Bristol Myers Squibb Share Price (BMY): Live Quote & Forecast

Bristol-Myers Squibb stock has logged a 20.8% gain over the past year, yet it trades roughly 52% below what analysts consider fair value. With a 4.26% dividend yield and a string of analyst upgrades and downgrades painting a mixed picture, the pharmaceutical giant sits at an interesting crossroads for investors willing to stomach some volatility.

Current Price: $59.13 ·
52 Week High: $62.89 ·
52 Week Low: $42.52 ·
P/E Ratio: 17.42 ·
Recent Change: -$1.04

BMY trades on the NYSE in the Health Care sector, with a 52-week range of $42.52–$62.89. The table below summarizes additional key metrics.

Is Bristol Myers a good stock to buy?

The short answer depends on what an investor is looking for. BMY currently offers a dividend yield of 4.26% — well above the S&P 500 average — and trades at roughly 52% below what Simply Wall St’s fair value estimate. That’s a substantial discount that catches the eye of value-focused investors.

The bull case hinges on that undervaluation, combined with a beta of just 0.27 — meaning BMY moves less than the broader market, making it a relatively defensive pharmaceutical play. StockAnalysis notes the consensus analyst rating sits at “Buy” with a 12-month target of $62.13, implying roughly 5.07% upside from recent levels.

Analyst ratings

Sixteen analyst firms have weighed in over the past year, creating a wide spread of opinions. The most bullish call came from Atlantic Equities, which issued a $85 price target on July 28, 2025 — roughly 44% above current trading levels. That optimism stands in sharp contrast to Citigroup’s November 17, 2025 rating, which set a $45 target while maintaining a neutral stance, citing -3.79% downside from that level.

The most recent major move was Goldman Sachs lowering its target from $67 to $55 on April 8, 2025 — a downgrade that arrived after the stock had climbed toward the top of its 52-week range. On the flip side, Jefferies had previously lifted its target to $70 from hold on December 16, 2024.

Value vs growth potential

Value investors see opportunity in BMY’s discount to intrinsic value. Growth investors, however, face headwinds: Simply Wall St projects earnings to decline 1.1% annually over the next three years, weighed down by loss of exclusivity on legacy drugs and ongoing pricing pressure. That forecast puts BMY firmly in turnaround territory rather than growth mode.

Why is BMS stock so low?

Bristol-Myers Squibb’s stock has been held back by a combination of structural challenges that have accumulated over several years. The most persistent is the “patent cliff” problem: older blockbuster drugs that once drove revenue are losing exclusivity, opening the door to generic competition that erodes both sales volumes and pricing power.

Legacy drug business struggles

Simply Wall St’s analysis flags that “loss of exclusivity and pricing pressures will erode revenue and margin growth, posing significant long-term financial headwinds.” This isn’t a new problem — it has been building for years as drugs like Revlimid and Abilify faced generic challengers — but the market continues to discount the stock accordingly.

High debt levels compound the issue. Simply Wall St notes that “large one-off items impacting results” have created noise in reported earnings, making it harder for investors to assess underlying performance. The balance sheet carries significant leverage, which constrains flexibility for acquisitions or share buybacks that might support the stock price.

Recent earnings impact

BMY closed at $58.54 on March 27, 2026, down 1.50% for the session, with the after-hours price slipping further to $58.31. The day’s trading range of $58.37–$59.69 shows the stock has stabilized within a narrow band, but the prior close of $60.17 and the $1.04 decline indicate recent selling pressure.

The pattern: price momentum pushed BMY toward the top of its 52-week range earlier in 2026, but resistance around $60–$62 has held. Earnings on April 30, 2026, will be the next major catalyst — any guidance below expectations could push the stock back toward the $50 support level or lower.

What is the future price of BMY stock?

Forecasting BMY’s trajectory requires separating near-term analyst targets from longer-term model estimates, which diverge dramatically. The near-term picture looks modest: the consensus from 34 analysts sits at $61.75, implying roughly 4% upside from current levels. That’s not a dramatic move, but it suggests the stock isn’t broken — it’s merely range-bound pending new catalysts.

Analyst predictions

Looking across the analyst landscape, the most relevant data points come from the past several months. Benzinga’s tracking shows 16 firms with active ratings, with the last upgrade by Jefferies on December 16, 2024, and the last downgrade by Goldman Sachs on April 8, 2025. Atlantic Equities issued its $85 target on July 28, 2025, while Citigroup set its more bearish $45 target on November 17, 2025.

The spread between the high ($85) and low ($45) targets — a $40 difference — underscores how much analyst opinion varies. This isn’t a case of consensus; it’s a case of deep disagreement about whether Bristol-Myers can successfully navigate its patent expirations.

Forecast models

Simply Wall St’s long-term model projects the stock at $10.68 by 2031, applying a 25.12x multiple. That projection assumes the earnings decline trajectory continues and that multiple compression occurs as growth disappears. It’s a scenario that assumes the dividend becomes unsustainable or is cut — a real risk if revenue falls far enough.

On the other hand, StockAnalysis maintains that BMY remains a “Buy,” highlighting the high dividend and free cash flow yield. The stock traded at $58.54 as of March 27, 2026, and the 1-year performance of +20.82% suggests the market has already rewarded some of the turnaround narrative.

The trade-off: near-term analysts see $61–$62; long-term models see structural decline. Investors must decide which timeframe matters more for their portfolio.

What is the Bristol Myers scandal?

The research turned up no evidence of a major recent scandal affecting Bristol-Myers Squibb stock. Benzinga’s analyst coverage and broader stock overviews make no mention of regulatory probes, accounting irregularities, or executive misconduct in recent periods. This doesn’t mean historical issues don’t exist — the pharmaceutical industry has seen its share of legal challenges — but nothing that rises to the level of a current “scandal” appears in the available data.

Investors searching for scandal-related concerns will find more relevant issues in the business fundamentals: patent expirations, pricing pressure, and debt levels rather than governance or ethical failures.

Should I buy, sell, or hold Bristol-Myers Squibb stock now?

The buy/sell/hold decision for BMY comes down to time horizon and income needs. For income-focused investors, the 4.26% dividend is compelling — it’s one of the higher yields in the pharmaceutical sector and suggests management still has confidence in the business generating sufficient cash to maintain the payout.

Investor considerations

For long-term investors willing to hold through volatility: the dividend provides a cushion, and if Bristol-Myers successfully launches new drugs, the discount to fair value could close. The ex-dividend date of April 2, 2026, is relevant for those targeting dividend capture.

For short-term traders: the $58–$63 range has held for months, suggesting a mean-reversion trading opportunity if the stock breaks decisively in either direction. Earnings on April 30, 2026, will likely be the next volatility catalyst.

For cautious investors: the structural headwinds are real. Loss of exclusivity, pricing pressure, and declining earnings suggest the stock may not be a bargain despite the discount — value traps exist in pharmaceuticals, and BMY fits that profile until proven otherwise.

Bristol Myers Squibb’s BMY shares, now at $59.13, draw similar scrutiny in Europe, where German stock analysis highlights oncology-driven trends and EUR forecasts.

Frequently asked questions

For investors evaluating international opportunities alongside BMY, understanding how currency conversion rates affect portfolio returns and comparing mortgage interest rates across markets can provide useful context for global diversification decisions.

“Bristol-Myers Squibb remains a ‘Buy,’ offering a high dividend and free cash flow yield amid recent market pullback.”

— StockAnalysis Analyst Summary

“Loss of exclusivity and pricing pressures will erode revenue and margin growth, posing significant long-term financial headwinds.”

— Simply Wall St Key Takeaways

For income-focused investors, the calculus is relatively straightforward: a 4.26% yield with strong institutional coverage beats most alternatives in this sector. For growth-oriented investors, the structural earnings decline and patent expirations make BMY a hold rather than a buy — until the pipeline produces concrete revenue numbers at the next earnings report on April 30, 2026, when the stock could break decisively above $62 if guidance impresses, or slide toward $50 if new drug launches disappoint.